Back to Journals » Patient Preference and Adherence » Volume 4

Multinational Internet-based survey of patient preference for newer oral or injectable Type 2 diabetes medication

Authors Marco daCosta DiBonaventura, Jan-Samuel Wagner, Cynthia J Girman, et al

Published 3 November 2010 Volume 2010:4 Pages 397—406

DOI https://doi.org/10.2147/PPA.S14477

Review by Single-blind

Peer reviewer comments 2

Marco daCosta DiBonaventura1, Jan-Samuel Wagner1, Cynthia J Girman2, Kimberly Brodovicz2, Qiaoyi Zhang3, Ying Qiu3, Sri-Ram Pentakota3, Larry Radican3
1Health Sciences Practice, Kantar Health, New York; 2Epidemiology, 3Global Health Outcomes, Merck, Whitehouse Station, New Jersey, USA

Background: The prevalence of Type 2 diabetes mellitus continues to rise. Although glucagon-like peptide-1 (GLP-1) analog and dipeptidyl peptidase-4 (DPP-4) inhibitor medications are effective, there are differences between these products, including method of administration (injectable versus oral). The objective of this study was to examine patient preferences (and predictors of preferences) for two different medication profiles, one similar to a GLP-1 analog (liraglutide) and another similar to a DPP-4 inhibitor (sitagliptin).
Methods: Internet survey data were collected in two waves (wave 1, n = 2402; wave 2, n = 1340) using patients from the US and Europe. Patients were presented with two hypothetical medication profiles (“drug A” and “drug B”, resembling sitagliptin and liraglutide, respectively) and asked to report their preferences.
Results: Most patients in wave 1 and wave 2 reported that overall they would prefer a drug with the sitagliptin-like profile (81.9% and 84.4%, respectively) over a drug with the liraglutide-like profile (18.1% and 15.6%, respectively), and >80% of patients reported that they would be able to take a drug with the sitagliptin-like profile as directed by their physician for a longer period. The likelihood of preferring the sitagliptin-like profile significantly increased as age (odds ratio [OR] = 1.02) and importance placed on method of administration (OR = 1.32) increased (P < 0.05). Although the sitagliptin-like profile was preferred by the majority of patients in all subgroups, a lower proportion of patients with obesity, with weight gain, with A1C values above target, and who exercised preferred the sitagliptin-like profile compared with those without obesity (77.0% versus 87.9%), without weight gain (77.8% versus 86.7%), with A1C values at or below target (79.0% versus 86.5%), and who did not exercise (81.6% versus 86.4%), respectively (P < 0.05).
Conclusions: This research suggests that patients (across geographies) prefer an oral medication with a profile resembling sitagliptin to an injectable medication with a profile resembling liraglutide.

Keywords: Type 2 diabetes, medication preference, sitagliptin, liraglutide

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

The association between lower back pain and health status, work productivity, and health care resource use in Japan

Sadosky AB, DiBonaventura M, Cappelleri JC, Ebata N, Fujii K

Journal of Pain Research 2015, 8:119-130

Published Date: 25 February 2015

The burden of insomnia in Japan

Mishima K, DiBonaventura MD, Gross H

Nature and Science of Sleep 2015, 7:1-11

Published Date: 5 January 2015

Impact of middle-of-the-night awakenings on health status, activity impairment, and costs

Moline M, DiBonaventura MD, Shah D, Ben-Joseph R

Nature and Science of Sleep 2014, 6:101-111

Published Date: 23 July 2014

The association between nonadherence and glycated hemoglobin among type 2 diabetes patients using basal insulin analogs

DiBonaventura M, Wintfeld N, Huang J, Goren A

Patient Preference and Adherence 2014, 8:873-882

Published Date: 19 June 2014

Characteristics, treatment patterns, and unmet needs of Japanese patients with atrial fibrillation [Corrigendum]

Koretsune Y, Rossi B, Iwamoto K, Wang ECY, DiBonaventura M, Briere JB

Research Reports in Clinical Cardiology 2014, 5:41-42

Published Date: 29 January 2014

Burden of comorbidities among Japanese patients with atrial fibrillation: a case study of dyspepsia [Corrigendum]

Kinoshita Y, DiBonaventura M, Rossi B, Iwamoto K, Wang ECY, Briere JB

Clinical and Experimental Gastroenterology 2013, 6:193-194

Published Date: 23 September 2013

Characteristics, treatment patterns, and unmet needs of Japanese patients with atrial fibrillation

Koretsune Y, Rossi B, Iwamoto K, Wang ECY, DiBonaventura M, Briere JB

Research Reports in Clinical Cardiology 2013, 4:97-105

Published Date: 4 July 2013

Burden of vasomotor symptoms in France, Germany, Italy, Spain, and the United Kingdom

DiBonaventura MD, Chandran A, Hsu MA, Bushmakin A

International Journal of Women's Health 2013, 5:261-269

Published Date: 24 May 2013

Burden of comorbidities among Japanese patients with atrial fibrillation: a case study of dyspepsia

Kinoshita Y, DiBonaventura M, Rossi B, Iwamoto K, Wang ECY, Briere JB

Clinical and Experimental Gastroenterology 2013, 6:51-59

Published Date: 20 May 2013

Burden of constipation-predominant irritable bowel syndrome (IBS-C) in France, Italy, and the United Kingdom

DiBonaventura MD, Prior M, Prieto P, Fortea J

Clinical and Experimental Gastroenterology 2012, 5:203-212

Published Date: 8 November 2012

The burden of chronic obstructive pulmonary disease among employed adults

DiBonaventura MD, Paulose-Ram R, Su J, McDonald M, Zou KH, Wagner JS, Shah H

International Journal of Chronic Obstructive Pulmonary Disease 2012, 7:211-219

Published Date: 19 March 2012

Readers of this article also read:

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010